Post
The Wall Street Journal
wsj.com
did:plc:i3fhjvvkbmirhyu4aeihhrnv
Nearly a fifth of patients exited the survodutide trial due to adverse gastrointestinal events such as nausea, vomiting and diarrhea, Boehringer said. on.wsj.com/3RT8zR2
https://on.wsj.com/3RT8zR2
2026-06-08T11:25:03.465Z